Drug intelligence / Profile preview

nab-paclitaxel + anthracycline + cyclophosphamide

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous

Overview

This combination involves **nab-paclitaxel**, a nanoparticle albumin-bound paclitaxel that stabilizes microtubules in cancer cells, preventing their disassembly and thus inhibiting cell division. **Anthracyclines** (e.g., doxorubicin, epirubicin) intercalate DNA strands, inhibiting the synthesis of nucleic acids and inducing apoptosis. **Cyclophosphamide** is an alkylating agent that cross-links DNA strands, leading to cell death. This combination is used in chemotherapy regimens, particularly for breast cancer.

Targets

DNAN7-G (DNA guanine-N7 adduct)TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on nab-paclitaxel + anthracycline + cyclophosphamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nab-paclitaxel + anthracycline + cyclophosphamide.

Explore the full profile